Approved in June for people at high risk of HIV, Yeztugo was shown to be nearly 100% effective at preventing infection in ...

Gilead stock toppled Thursday on a report CVS won't add the company's new HIV prevention drug, Yeztugo, to its commercial ...

E xecutives at Gilead Sciences, the biotech behind a long list of HIV treatments and preventative medicines, have spoken with great optimism in recent weeks about the prospects that insurers will ...

The owner of the United States' largest pharmacy benefit manager (PBM) is declining to cover Gilead Sciences’ long-acting HIV ...

CVS Health (CVS) won't include Gilead's (GILD) new HIV drug Yeztugo in its commercial healthcare plans, due to clinical, ...

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's proven effectiveness ...

Market Catalysts Host Julie Hyman recaps some of the trending tickers on Thursday, Aug. 21, including Coty (COTY), Gilead ...

CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.

Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) fell 3.5% in the morning session after reports that CVS Health will not be adding the company's new HIV prevention drug, Yeztugo, to ...

Investing.com -- Gilead Sciences (NASDAQ: GILD) stock fell 2.7% in pre-market trading Thursday after reports that CVS Health (NYSE: CVS) will not add the company’s new HIV prevention drug, Yeztugo, to ...

Gilead Sciences is accelerating its growth rate and Yeztugo might be another major blockbuster. GILD stock is still trading ...

Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year ...